Experimental amounts
Published amounts for CJC-1295
The most misleading number is an amount separated from its experiment. The human pharmacology studies and the GHRH-deficient mouse study had different subjects and different purposes.
CJC-1295 dosage in volunteer studies
Teichman and colleagues studied 30 or 60 micrograms per kilogram in healthy adults, using subcutaneous administration. Ionescu and Frohman studied a single subcutaneous administration of 60 or 90 micrograms per kilogram in healthy men. The amounts were weight-based and used to examine hormone responses and drug persistence.
I read these figures as descriptions of experiments. CJC-1295 has no approved human treatment dose. The human papers cannot provide an individual treatment plan, and controlled human trials have not established an amount for the CJC-1295/ipamorelin combination.
The GHRH-knockout mouse amounts
In Alba and colleagues’ study, GHRH-knockout mice received 2 micrograms per administration. The tested intervals were 24, 48 or 72 hours. Administration every 24 hours fully normalized body weight and length; the longer intervals were progressively less effective. Pituitary GH mRNA, the cellular instructions for producing growth hormone, also increased.
The contrast between intervals is scientifically interesting because the compound was designed to last. Its limitation seems equally clear to me: impaired growth in mice missing GHRH. That animal result establishes no human treatment schedule.
Route, duration and handling
The human studies placed the drug beneath the skin. Earlier pharmacokinetic work on GRF(1-29), a different substance, also used intravenous delivery. Those descriptions identify research routes, without establishing a personal injection location or method.
The research account describes freeze-dried peptide prepared with bacteriostatic water and refrigerated during laboratory handling. Oral bioavailability is negligible because the peptide is broken down during digestion. These details provide background to the compound’s chemistry, and supply no home preparation instructions.
The DAC half-life estimate of 5.8-8.1 days concerns the long-acting form. Modified GRF 1-29 lacks its albumin attachment. The form comparison explains why the human DAC figures cannot simply be transferred to the no-DAC form.